New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:05 EDTRXIIRXi Pharmaceuticals granted patent for fibrosis treatment technology
RXi Pharmaceuticals has been granted a patent by the USPTO on its unique self-delivering RNAi compounds, for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. The patent will expire in 2029.
News For RXII From The Last 14 Days
Check below for free stories on RXII the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
07:15 EDTRXIIRXi Pharmaceuticals initiates third Phase 2a study for hypertrophic scars
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use